Literature DB >> 8056579

Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy.

S U Berlangieri1, D M Brizel, R L Scher, T Schifter, T C Hawk, S Hamblen, R E Coleman, J M Hoffman.   

Abstract

BACKGROUND: Positron emission tomography (PET) provides a noninvasive modality for evaluating the biochemical processes of normal and pathologic tissue. Preliminary reports of F-18 fluorodeoxyglucose (FDG) PET indicate its potential usefulness in evaluating head and neck tumors. The current study was performed to explore the relationship between changes in tumor FDG metabolism and local control in patients receiving hyperfractionated radiotherapy and concurrent chemotherapy.
METHODS: The study group consisted of six patients with locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. FDG studies were performed prior to, during, and 24 months post-therapy. Ratios of tumor to nontumor FDG uptake in regions of interest (ROI) were compared.
RESULTS: All pretherapy studies demonstrated a focal hypermetabolic abnormality corresponding to the known tumor. The pretherapy tumor to nontumor FDG ratios declined significantly during therapy (p < 0.05) with a similar continued trend post-therapy (p < 0.07).
CONCLUSION: The treatment-induced decrease in tumor hypermetabolism as seen on serial FDG PET parallels the clinical response in squamous carcinoma of the head and neck. Two-year follow-up scans also suggest that continued low tumor to nontumor ratios reflect eradication of local disease. Because of its high cost, a study of larger numbers of patients is necessary to better define the role of PET in the management of head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8056579     DOI: 10.1002/hed.2880160408

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome.

Authors:  Ian Ganly; Jennifer Bocker; Diane L Carlson; Salvatore D'Arpa; Maria Coleman; Nancy Lee; David G Pfister; Jatin P Shah; Snehal G Patel
Journal:  Head Neck       Date:  2010-11-04       Impact factor: 3.147

2.  Assessment of induced rat mammary tumour response to chemotherapy using the apparent diffusion coefficient of tissue water as determined by diffusion-weighted 1H-NMR spectroscopy in vivo.

Authors:  L Lemaire; F A Howe; L M Rodrigues; J R Griffiths
Journal:  MAGMA       Date:  1999-03       Impact factor: 2.310

Review 3.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

4.  [Diagnosis with (18)F-FDG PET scan after larynx preservation by primary radiochemotherapy].

Authors:  A Dietz; V Rudat; W Harms; M Jungehülsing; R Dollner; M Henze
Journal:  HNO       Date:  2004-01       Impact factor: 1.284

5.  Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in 18fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer.

Authors:  Shang-Wen Chen; Ying-Chun Lin; Rui-Yun Chen; Te-Chun Hsieh; Kuo-Yang Yen; Ji-An Liang; Shih-Neng Yang; Yao-Ching Wang; Ya-Huey Chen; Nan-Haw Chow; Chia-Hung Kao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-16       Impact factor: 9.236

6.  Comparison between PET and PET/CT in recurrent head and neck cancer and clinical implications.

Authors:  Nicolas Fakhry; David Lussato; Thierry Jacob; Roch Giorgi; Antoine Giovanni; Michel Zanaret
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-01-04       Impact factor: 3.236

7.  Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo.

Authors:  M Zhao; J G Pipe; J Bonnett; J L Evelhoch
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.